

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **INSIDE INFORMATION: PROGRESS ON SUSPENSION OF TRADING OF A SHARES REGARDING THE PLAN FOR SIGNIFICANT TRANSACTION**

This announcement is made by the board of directors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 30 October 2017 in relation to the suspension of trading of A shares regarding the plan for significant transaction and the announcement of the Company dated 6 November 2017 in relation to the progress on suspension of trading of A shares regarding the plan for significant transaction. As the Company is contemplating a significant transaction, after application made by the Company to the Shanghai Stock Exchange, trading in the Company’s A shares has been suspended since 31 October 2017.

As at the date of this announcement, the significant transaction is primarily in relation to the proposed acquisition (the “**Proposed Acquisition**”) by the Company of certain equity interest in Guangzhou Pharmaceuticals Corporation (“**GP Corp**”). The consideration for the Proposed Acquisition is proposed to be satisfied by the Company in cash. As at the date of this announcement, GP Corp is a jointly controlled entity of the Company, in which the Company holds 50% equity interest. Based on the information available to the Company as at the date of this announcement, the Proposed Acquisition, if occurs, may constitute a very substantial acquisition of the Company under Chapter 14 of the Listing Rules. No legally binding agreement(s) (whether in respect of the percentage of the equity interests of the target company proposed to be acquired by the Company, consideration, manner of payment of the consideration or otherwise) in this regard has been entered into by the Company as at the date of this announcement.

Given the uncertainty in relation to the Proposed Acquisition and in order to ensure fair disclosure of information, safeguard the interests of investors and prevent unusual fluctuation in the price of the A shares of the Company, the trading in the Company’s A shares will continue to be suspended. However, trading of the Company’s H shares has not been suspended.

The Company undertakes that during the period of suspension of trading of the Company's A shares, the Company will perform its obligations to disclose information in a timely manner in accordance with the relevant laws and regulations and will make an announcement on the progress of the significant transaction at the interval of five trading days of A shares.

**There is no assurance that the significant transaction will either materialise or eventually be consummated. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 13 November 2017

*As at the date of this announcement, the board of directors of the Company comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.*